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Objectives: Some patients with surgically resected stage I non-small-cell lung
cancer eventually have metastatic disease. A histologic marker of metastatic
potential and diminished survival for stage I non-small-cell lung cancer may
distinguish this patient population. This study evaluates the degree of angio-
genesis as a predictor of cancer-related death after operation for stage I
non-small-cell lung cancer. Methods: Demographic, surgical, and histopatho-
logic data, including presence of vascular invasion, were reviewed for 106
patients with stage I non-small-cell lung cancer from 1985 through 1990.
Visual quantitation of microvessels immunostained with factor VIII–related
antigen and CD31 in 5 mm sections from the paraffin blocks of tissue defined
rumor angiogenesis. Results: Follow-up was 95.1% complete, mean 5.2 6 3.0
years. Lung cancer-related mortality rate was 24.4% at 5 years. Mean mi-
crovessel counts were 20.7 6 11.2 for FVIII and 29.6 6 18.1 for CD31.
Univariate analysis revealed an FVIII count of at least 20 (p 5 0.025) and blood
vessel invasion (p 5 0.017) to be significant predictors of disease-related death.
After adjustment for other patient and tumor characteristics, multivariate Cox
regression analysis found an FVIII count of at least 20 (hazard ratio 2.9) and
blood vessel invasion (hazard ratio 3.7) to be significant independent corre-
lates of lung cancer death (p 5 0.018 and p 5 0.011, respectively). CD31
quantitation did not predict survival on univariate or multivariate analyses
and did not correlate strongly with FVIII quantitation (Spearman’s rank
correlation r 5 0.19). Conclusions: This analysis reveals a significant associa-
tion between tumor neovascularization and cancer-related mortality rate
among patients with stage I non-small-cell lung cancer. Microvessel quantita-
tion of FVIII, as an indicator of tumor angiogenesis and metastatic potential,
may define a subset of patients with stage I non-small-cell lung cancer who
could benefit from adjuvant therapy after surgical resection. (J Thorac
Cardiovasc Surg 1998;115:652-9)
Solid tumor growth and development have beenassociated with an initial prevascular stage (slow,
local growth), followed in many cases by a vascular
phase characterized by neovascularization of the tu-
mor mass (rapid, distant spread).1-5 Although this
angiogenesis alone is not sufficient for metastasis to
occur, it has been correlated with increased incidence
of metastasis. Immunostaining of endothelial cells
from invasive portions of resected oncologic speci-
mens permits visualization of microvessels whose for-
mation is induced by tumor–host cell interactions.6, 7
Quantitation of immunostained microvessels has since
become an indicator of the degree of neovasculariza-
tion and thus tumor metastatic potential.7-12
The value of angiogenesis as a significant prog-
nostic marker of outcome after resection of solid
tumors becomes potentially crucial in assigning ther-
apy to patients with early-stage cancer for whom
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surgery alone is expected to be curative. Despite a
20% to 40% recurrence rate within 5 years of
operation, patients with stage I non-small-cell lung
cancer (NSCLC) in particular are typically treated
with surgical resection alone.13-17 Various biologic
markers have been examined as prognostic indica-
tors of recurrent disease and diminished survival in
patients with primary lung cancer, including deoxyri-
bonucleic acid ploidy, oncogene derangements,
blood group antigens, and tumor cell antigens,
among others.18-21 Few, however, have examined
the significance of neovascularization in a specific
subset of patients with early evidence of
NSCLC.22-26
This investigation evaluated the prognostic signif-
icance of tumor angiogenesis in patients with stage I
(T1 N0 M0 and T2 N0 M0) NSCLC who underwent
surgical resection alone between 1985 and 1990.
Furthermore, we analyzed immunostaining for fac-
tor VIII-related antigen (FVIII) and for CD31
platelet-endothelial cell adhesion antigen (CD31)
with respect to clinical outcome.12, 27
Materials and methods
Study population. The Emory University Hospital On-
cology Registry provided 112 consecutive patients who
underwent surgical resection for stage I NSCLC between
1985 and 1990, without postoperative or neoadjuvant
therapy. The clinical records of these patients were re-
viewed to obtain routine demographic information and
confirm accurate clinical and pathologic tumor staging.
Operative procedure. The location of the carcinoma
was recorded from the preoperative evaluation and ad-
justed according to intraoperative findings as necessary. In
agreement with institutional policy, lobectomies or pneu-
monectomies were typically performed as dictated by
tumor size and location. Wedge resections or segmentec-
tomies were performed in cases of small, peripheral,
superficial lesions, or in conditions of diminished pulmo-
nary reserve. Intraoperative staging included hilar and
mediastinal lymph node sampling.
Follow-up. Follow-up of the study population was con-
ducted by direct patient contact. Patients were categorized
as alive with evidence of disease, alive without disease,
dead as a result of lung carcinoma, or dead of unrelated
causes. Time in days from the date of the operation to the
date of follow-up or death was recorded.
Histopathologic evaluation. After approval was ob-
tained from the Institutional Review Board Human Tis-
sue Use Committee, formalin-fixed, paraffin-embedded
blocks of tumor tissue taken at the time of operation were
used for this analysis. Maximum size of the tumor in the
resected specimens was documented from the original
pathologic report. Representative hematoxylin-eosin—
stained sections were reviewed to confirm histologic cell
type and visceral pleural invasion.
Immunohistochemistry. Areas representative of the tu-
mor’s invasive component were identified.8 Five microme-
ter sections of formalin-fixed, paraffin-embedded tissue
were tested for the presence of immunohistochemically
detectable antigens with monoclonal anti-FVIII (predi-
luted; Ventana Medical Systems, Inc., Tucson, Ariz.) with
pepsin digestion and with monoclonal anti-CD31 (1/80;
Dako Corporation, Carpinteria, Calif.). An avidin-biotin-
ylated enzyme complex kit (Signet Laboratories, Inc.,
Dedham, Mass.) was used, with previous heat antigen
retrieval with the automated TechMate 1000 immuno-
staining systems (Ventana Medical Systems).
Sections were removed from paraffin and rehydrated,
then steamed in citrate buffer for 20 minutes and cooled
for 5 minutes before immunostaining. All tissues were
then exposed to blocking antibody for 5 minutes, primary
antibody for 25 minutes, biotinylated secondary linking
antibody for 25 minutes, hydrogen peroxide solution for
7.5 minutes, avidin-biotinylated enzyme complex for 25
minutes, diaminobenzidine as chromogen for 15 minutes,
and hematoxylin as counterstain for 1 minute. These
incubations were performed at room temperature; be-
tween incubations, sections were washed with buffer.
Sections of myometrium with blood vessels were used as
positive control preparations; antibody was replaced by
buffer in negative control preparations.
Only tissues with high-quality staining of the microves-
sel component were viewed. Light microscopy at low
power (340) was used to locate areas of tumor containing
the most capillaries and small venules, areas of highest
neovascularization, to be used for microvessel quantita-
tion. A microvessel was defined as any brown-staining
endothelial cell cluster separate from adjacent microves-
sels, tumor cells, and other connective tissue stromal
elements. The presence of a vessel lumen was not neces-
sary for a structure to be defined as a microvessel. A single
3200 field, 0.74 mm2 area, was simultaneously counted by
Table I. Patient and operative demographics (n 5
106)
Variable No. %
Sex
Male 66 62.3
Female 40 37.7
Age (yr)
#60 36 34
.60 70 66
Site of primary tumor
Right 61 57.5
Left 45 42.5
Extent of operation
Wedge/segmentectomy 11 10.3
Lobectomy 89 84
Pneumonectomy 6 5.7
Maximum size (cm)
#3 71 69.6
.3 31 30.4
T status
T1 63 59.4
T2 43 40.6
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two investigators with a double-headed light microscope.
Each individual count was recorded, and results were
displayed as the mean of the two measurements. The
investigators were unaware of the patient’s clinical out-
come.
Tumor vessel invasion. From the representative hema-
toxylin-eosin–stained sections, the presence of tumor cell
emboli in endothelial-lined channels was determined by
identification of intratumoral lymphatic vessel invasion
and blood vessel invasion. Lymphatic vessel invasion was
differentiated from blood vessel invasion according to
previously reported morphologic characteristics.28, 29
Statistical analysis. Univariate correlates of cancer-
related mortality rate were found with the log-rank test,
and univariate (unadjusted) Kaplan-Meier curves were
derived. The multivariate (adjusted) correlates of cancer-
related mortality rate were found with the Cox propor-
tional hazards regression, where the hazard of cancer-
related death was modeled. The results were displayed in
terms of hazard ratios, ratios of the hazard of cancer-
related death for patients with and without a characteristic
present, and the 95% confidence interval. All tests were
two-tailed. All missing data were assumed to be missing at
random. Spearman’s rank correlation was used for evalu-
ation of correlation between FVIII and CD31 manual
counts. The S-Plus statistical software (MathSoft, Inc.,
Seattle, Wash.) was used for all analyses.
Results
Six patients were excluded from the original co-
hort found in the tumor registry because review of
Fig. 1. Kaplan-Meier actuarial survival curves for survivors past hospitalization. A, Overall survival; B,
lung cancer–related mortality rate.
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their medical records and histopathologic reports
revealed evidence of disease beyond stage I. A total
of 106 patients with stage I NSCLC were available
for evaluation. This constitutes 26.6% (106/398) of
all patients who underwent operation for primary
lung carcinoma at our institution between 1985 and
1990. Operative mortality rate for the study popu-
lation was 2.8% (3 of 106). Patient and operative
demographic data are displayed in Table I.
Follow-up was complete for 95.1% (98/103) of the
survivors past hospital stay for a median 5.5 years
and as long as 11.1 years. Fig. 1 (A) displays the
Kaplan-Meier survival curve for the 98 survivors
past hospital stay. Overall survivals were 55.1%at 5
years and 28.7% at 10 years. Lung cancer-related
mortality rate was 24.4% at 5 years after the oper-
ation, with no cancer-related deaths found after 6
years (Fig. 1, B). An additional three patients were
found to be alive with evidence of recurrent or
metastatic disease at follow-up.
Histopathologic data are presented in Table II.
Degree of angiogenesis, according to microvessel
quantitation, is shown in Table III. FVIII quantita-
tion could not be performed for five of the 106
specimens because of the poor quality of immuno-
staining in those specimens (mean count 20.74 6
11.2). Similarly, only 103 of the 106 samples could
be evaluated for CD31 manual quantitation (mean
count 29.6 6 18.1). The range of manual counts of
microvessels immunostained for CD31 was broader
than for FVIII (8 to 125.5 and 3.5 to 57.5, respec-
tively). Test results for replication reproducibility
were strongly positive between the two observers for
both FVIII and CD31 manual counts (interclass
correlation coefficient 0.97 for each). However,
FVIII and CD31 manual counts revealed only a
slight positive correlation (r 5 0.19; Fig. 2).
Univariate analysis revealed a mean FVIII count
greater than 20 and the presence of blood vessel
invasion to be significant predictors of disease-
related death (p 5 0.025 and p 5 0.017, respectively;
Fig. 3). CD31 manual quantitation, however, failed
to predict tumor-related death (p 5 0.34; Fig. 4).
Tumor histology (p 5 0.41), size greater than 3 cm
(p 5 0.72), grade (p 5 0.68), presence of visceral
pleural invasion (p 5 0.56), and lymphatic vascular
invasion (p 5 0.10) were similarly not associated
with diminished disease-related survival in this co-
hort. Multivariate Cox regression analysis consid-
ered all variables listed in Tables I through III as
possibly predicting patient outcome. Tumor angio-
genesis, as determined by FVIII count greater than
20 and the presence of blood vessel invasion, were
the only significant independent prognostic markers
of disease-specific death (Table IV).
Discussion
Despite complete surgical resection of localized
stage I NSCLC, as many as 40% of patients have
recurrent, typically distant disease and eventually
die of lung cancer. A readily obtainable index for the
risk of subsequent disease could conceivably define
a patient population that could benefit from adju-
vant therapy. Oncogenic abnormalities, deoxyribo-
nucleic acid ploidy, cell replication indexes, and
other molecular and pathologic tumor characteris-
tics have all been identified as markers of aggressive
disease and diminished survival among patients with
primary lung carcinoma.18-20 In addition, neovascu-
Table II. Histopathologic features (n 5 106)
Characteristic No. %
Histology of carcinoma
Adenocarcinoma 63 59.4
Squamous cell 30 28.3
Bronchioalveolar 5 4.7
Large cell 5 4.7
Adenosquamous 3 2.8
Grade of differentiation
Poor 35 33
Poor to moderate 9 8.5
Moderate 38 35.8
Moderate-to well 3 2.8
Well 11 10.4
Bronchioalveolar
Serous 4 3.8
Mucinoid 1 0.9
Visceral pleural invasion
Presence 20 19.2
Absence 84 80.8
Blood vessel invasion
Presence 11 10.5
Absence 94 89.5
Lymphatic vessel invasion
Presence 21 20.2
Absence 83 79.8
Table III. Angiogenic activity
Manual counts No. %
FVIII
,20 54 56.3
$20 42 43.7
CD31
,30 67 68.4
$30 31 31.6
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Fig. 2. Relationship of FVIII and CD31 manual counts.
Fig. 3. Kaplan-Meier survival curves describing freedom from lung cancer–related death. A, By FVIII
manual quantitation; B, by blood vessel invasion (BVI).
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larization has been described as a critical compo-
nent of tumor proliferation and metastasis, impli-
cated in the outcome after treatment of a variety of
solid tumors.7-12
In our analysis of 106 consecutive patients with
stage I (T1 N0 M0 and T2 N0 M0) NSCLC, FVIII
manual quantitation as a marker of tumor angiogen-
esis was revealed to be a significant independent
predictor of lung cancer–related death. Blood vessel
invasion was also an independent marker for dis-
ease-related death. These findings attest to the
significance of the development of new capillary
blood vessels and vascular invasion in solid tumor
dissemination and metastasis. Other histologic vari-
ables reviewed, including tumor histology, grade,
size, and visceral pleural invasion, were not associ-
ated with diminished late survival in these patients
with stage I disease. Similarly, patient age, location
of primary tumor, and operative procedure per-
formed were not related to survival after resection.
The technique of immunostaining for CD31,
rather than FVIII, as the microvessel marker for
manual quantitation has recently been promoted on
the perceived basis of enhanced sensitivity and
specificity of endothelial cell staining.12, 27 FVIII is
known to cross-react with megakaryocytes, platelets,
and lymphatic endothelial cells. In an analysis of 103
patients with primary breast cancer, Horak and
colleagues27 describe the CD 31 monoclonal anti-
body as more specific than FVIII immunostaining
for the determination of angiogenesis. They report,
however, that CD31 is also expressed during my-
elomonocytic cellular differentiation, and conse-
quently may cross-react with plasma cells, platelets,
neutrophils, peripheral T cells, and mantle zone B
cells. Use of CD31 monoclonal antibody immuno-
staining for assessment of lung cancer neovascular-
ization has not been previously described. In our
review, manual quantitation of CD31-stained mi-
crovessels proved cumbersome, with higher counts
than for FVIII. This was most likely because of both
the increased sensitivity to endothelial cells and the
inability to discriminate possible cross-reaction with
plasma cells, tumor cells, and fibroblasts. As such,
there was a wide range of FVIII values for any given
CD31 manual count, with only a weak correlation
between the two techniques. Most significantly, an-
giogenesis as assessed by CD31 microvessel quanti-
tation was not predictive of late death from lung
cancer in this cohort.
The degree of tumor neovascularization and the
Fig. 4. Kaplan-Meier curve describing freedom from lung cancer–related death by CD31 manual
quantitation.
Table IV. Significant independent predictors of lung
cancer–related death
Characteristic Hazard ratio
95%
Confidence
Interval p Value
FVIII count $20 2.9 1.2, 6.8 0.018
Blood vessel invasion 3.7 1.4, 10.1 0.011
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presence of blood vessel invasion were predictive of
late disease-related death for patients with stage I
NSCLC. Manual quantitation of microvessels after
FVIII immunostaining but not CD31 immunostain-
ing was a reliable marker of angiogenesis as it
related to late outcome. Tumor angiogenesis may
serve to mark patients at risk of recurrent disease
after complete surgical resection and should be
considered in future prospective studies selecting
patients for adjuvant therapy.
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Discussion
Dr. E. Carmack Holmes (Los Angeles, Calif.). The
Emory group has looked at the prognostic significance of
tumor angiogenesis in 106 patients with resected stage I
lung cancer, and they have used two monoclonal antibod-
ies directed against FVIII and CD31, both of which have
specificity for endothelial cells. These two antibodies can
be used to quantitate angiogenesis, and this article con-
cludes that angiogenesis is the strongest independent
indicator of cancer-free survival in patients with resected
stage I lung cancer.
Patients with stage I lung cancer that stained positively
with FVIII antibody had a cancer-free survival of 66%,
and those with negative stain results had a survival of
83%. That is almost a 20% higher survival in marker-
negative patients.
Now, evidence is rapidly accumulating that molecular
markers may replace standard histopathology in predict-
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ing survival. This article is the sixth in recent years to show
a strong survival correlation with immunostaining for
angiogenesis. If you add other prognostic molecular mark-
ers, such as the proto-oncogene HER-2/neu and the tumor
suppressor gene p53, then the prognostic power is greatly
enhanced.
In a recent article by Harpole and coworkers, they
showed that when none of the markers that I mentioned
before in addition to angiogenesis were positive, survival
in stage I was 80%; when all four molecular markers were
positive, survival dropped to 50%. This is a full 30%
difference in the marker-negative patients, and the mark-
er-positive patients probably should receive adjuvant ther-
apy. Indeed, it is becoming quite clear that measurements
of tissue molecular markers will more directly assess the
aggressiveness of a tumor than will standard histologic
examinations.
Dr. Duarte, have you looked at other molecular mark-
ers? This certainly will enhance the power of the predict-
ability of the molecular markers.
Also, I am perplexed as to the reason that the CD31
antibody did not correlate and the staining was unreliable.
You referred to this in your presentation and proposed
certain reasons why this was the case, but I might suggest
another, and perhaps you would comment on it. As you
know, Horak and colleagues showed a high correlation
with metastatic disease with the CD31 antibody, at least in
breast cancer. I suggest that some techniques different
between your study and their study might explain the
differences in your findings. First, the antibody concentra-
tions in your study and their study were different; also, the
retrieval method, that is, pepsin in your study and pro-
tease type 24 in theirs, may well have contributed to the
differences in the two studies.
Finally, I would like to make a comment. I think this
article would be greatly enhanced, Dr. Duarte, if there
were a more vigorous discussion comparing your study
and its results with previous publications on the same
subject.
Dr. Ali Nur Rahman (Manchester, England). We are
naturally interested in this important piece of work,
because England harbors one of the highest incidences of
cancer in the world.
I am just wondering about the mechanism of reduced
survival in these cases. If it is by angiogenesis, has it
already metastasized? If so, has there been any evidence
of magnetic resonance imaging scanning, even though the
renal glands, I assume, were negative? Is there any way of
indicating whether it has already metastasized? How do
these patients die in the end, from a second disease after
the tumor has been removed, I assume, completely?
Dr. Mark K. Ferguson (Chicago, Ill.). Have you ana-
lyzed whether there is a correlation between FVIII stain-
ing and blood vessel invasion?
Dr. Duarte. I will try to answer Dr. Holmes’ questions in
order. With respect to whether we have looked at other
markers, at this time we have not. Indeed, he referred to
Harpole and the group from Boston, where p53 abnor-
malities and c-erbB2 proto-oncogene overexpression, as
well as angiogenesis, were found to be significant inde-
pendent predictors. We have not done that at this time. It
is something we are considering doing in subsequent
studies, perhaps including it in a model of selecting
patients who may benefit from adjuvant therapy.
With respect to the CD31 antibody, we found differ-
ences in our technique of immunostaining and of tissue
digestion from those of Horak and coworkers, who first
described using CD31 monoclonal antibody in patients
with breast cancer. As I have shown, however, we were
able to have effective, adequate immunostaining in 103 of
the 106 lung cancer tissue specimens with monoclonal
CD31. Perhaps some degree of the differences in results
can be attributed to protein digestion differences and
dilutional differences in the use of this antibody, but I
suspect not.
In addition, Horak and coworkers reported in that
article that CD31 is considered more sensitive for endo-
thelial cells. Noel Weidner and the group from Boston,
however, have reported (as does the antibody manufac-
turing sheet that comes with it) that it also stains
megakaryocytes, platelets, tumor cells, fibroblasts, and
particularly plasma cells. In doing the actual manual
quantitation, it was sometimes difficult to discriminate
which were plasma cells, fibroblasts, and so on, versus
tumor cells stained. As a measure of reproducibility
between the two observers, the interclass correlation
coefficient was 0.97. So, despite this cross-reaction, the
two observers were counting the same immunostains as a
vessel or as some other cross-reactivity cell. I suspect,
though, that the failure of CD31 to show significance here
may have been caused primarily by that cross-reaction.
Last, with respect to CD31, personal communications
from other individuals, particularly those in the depart-
ment of pathology that have used CD31 specifically in
lung cancers, have also noted failure to show a significant
positive relationship between CD31 and survival. In fact,
our pathologists at Emory recently reported an inverse
relationship, actually, with image cytometry rather than
manual quantitation.
With respect to the mechanism of angiogenesis raised
by the other discussant, angiogenesis is considered one of
the earlier phases of tumor development and growth. It
precedes the development of metastasis. It is the process
by which the tumor induces blood vessels to form to it,
typically from the parenchymal capillaries and postcapil-
lary venules. Different modalities, rather than simple
histologic analysis of nodes from the intraoperative dis-
section, have been used to try to identify positive nodal
metastases in patients by means of particular immuno-
stains and antibodies. The association between microves-
sel quantitation, angiogenesis, and nodal metastasis or
systemic micrometastasis with these sensitive techniques
has not yet been evaluated. In all of these cases, the nodes
that were all reexamined were all negative for cancer.
With respect to Dr. Ferguson’s question, there was no
significant association between FVIII counts and the
presence of blood vessel invasion, nor with the presence of
lymphatic vessel invasion, tumor size, or T status. It was
truly an independent predictor of outcome.
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